

Company number: 7487432
Charity number: 1139869
Charity number Scotland: SCO44260



Sarcoma UK
Annual Report and Accounts
For the Year Ended 31 March 2020

CONTENTS

	Page
Chair of Trustees' Statement	3
Reference and Administrative Details	4
Report of the Trustees:	5 - 28
Objectives and activities	
Achievements and performance	
Future plans	
Governance, structure and management	
Financial Review	
Statement of responsibilities of the trustees	
Acknowledgements	29 – 32
Independent Auditor's Report to the Members of Sarcoma UK	33 - 36
Financial Statements:	37 - 50
Statement of financial activities	
Balance sheet	
Statement of cash flows	
Notes to the financial statements	

Chair of Trustees' Statement

The last year has been a period of incredible highs and tragic lows.

As the COVID-19 pandemic impacted on all parts of society towards the end of March, our Support Line and information services were overwhelmed by increased demand. Calls to our helpline increased by over 70% as anxious patients saw their treatments stopped or postponed and were worried about shielding and disruptions to their treatment and care. Patients with suspected sarcomas were given telephone consultations or told to watch and wait until they could be examined or scanned.

Working with the One Cancer Voice coalition and NHS England, Sarcoma UK produced information for our patients and did what we could to guide patients and encourage anyone with a suspected cancer to consult with their GP as soon as possible.

The charity also lost a dear supporter and former trustee in January when our friend Ian Hughes died of a brain tumour. Ian was a fellow trustee until October 2019 and he was a passionate supporter of our work. He will be sorely missed by everyone at the charity.

Despite these challenging times Sarcoma UK achieved a great deal in 2019-20. In a difficult year, the charity surpassed all of the targets we set ourselves.

- We invested £923,000 in pioneering sarcoma research (an increase of over 40% on last year).
- We helped over 720 patients through our Support Line, 2,800 times. We expanded our opening hours and 90% of those questioned said the Support Line had helped them.
- We introduced a new Policy and Public Affairs function. Early impacts include helping launch a National Sarcoma Service Specification and successfully encouraging the Royal College of Obstetricians and Gynaecologists to change their morcellation guidance.
- We successfully rebranded the charity and attracted new supporters.
- Our first policy report formed the backbone of an awareness campaign called *The Loneliest Cancer*. It received over 50 pieces of coverage including The Telegraph, ITV and Mirror. Additionally, the total radio reach for the campaign was over 28 million.
- We held successful stewardship events including a 10 Downing Street reception and our first ever Carol Concert and Glitter Ball.

We grew our income by 45% (£1.8m to £2.7m). This was testament to the hard work and dedication of our wonderful supporters who ran marathons, held picnics and abseiled down buildings like never before.

As I come to the end of my term as Chairman of the charity, I am proud of what we have achieved. The challenges presented by the global pandemic are considerable but I am confident that we have the team and loyal supporters to see us through and we will emerge in 2021 a stronger, bolder charity. Next year we will celebrate our tenth anniversary – we have achieved much in our first ten years but there is still so much more to do.

Glyn Wilmshurst
Chair of Trustees

Reference and Administrative Details

Company number	7487432 (Limited by guarantee in England and Wales)
Charity number	England and Wales (1139869) Scotland (SCO44260)
Registered office	49-51 East Road, London N1 6AH
Trustees	Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows: Glyn Wilmshurst (Chair) Sarah Conneally Andy Eckles Professor Rob Grimer (term of office ended October 2019) Ian Hughes (term of office ended October 2019) Professor Ian Judson Louisa Nicoll Sam Patton (appointed October 2019) Sharon Reid Isla Robinson (appointed October 2019) Anjula Thompson Johanne Vass Dr Jeff White (term of office ended March 2020) Sam Whittam Russ Wilson (appointed March 2020)
Patron	Richard Whitehead MBE
Chief Executive	Richard Davidson
Company Secretary	Katy Drake and Karen Wines
Bankers	CAF Bank Ltd, 25 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4JQ Lloyds TSB, National Clubs & Charities, PO Box 1000, BX1 1LY
Solicitors	Brahams Dutt Badrick French LLP, 24 Monument Street, London, EC3R 8AJ
Auditor	Sayer Vincent LLP Chartered accountants and statutory auditors Invicta House 108-114 Golden Lane London EC1Y 0TL

Objectives and Activities

Sarcoma UK is the only cancer charity in the UK focusing on all types of sarcoma.

Our vision

Our vision is a world where everyone affected by sarcoma cancer has the treatment, care and support they need.

Our mission

Our mission is to ensure everyone affected by sarcoma receives the best treatment, care, information and support available and to create the treatments of the future.

Our goals

1. More people will survive sarcoma.
2. More will be known about the causes of sarcoma.
3. Everyone affected by sarcoma will have access to the best treatment and care.

What we do

- Drive awareness of sarcoma cancer.
- Find answers through funding sarcoma research.
- Provide information and support to anyone affected by sarcoma cancer.
- Campaign for better treatments and to improve standards of care.

Sarcoma facts and figures

1. Sarcomas are uncommon cancers that can affect any part of the body, on the inside or outside, including the muscle, bone, tendons, blood vessels and fatty tissues.
2. Fifteen people are diagnosed with sarcoma every day in the UK. That's about 5,300 people a year.
3. There are around 100 different sub-types of sarcoma.
4. A key symptom of sarcoma is a lump that is increasing in size, often quickly.
5. Sarcoma diagnoses now make up about 1.4% of all cancer diagnoses in the UK.
6. Sarcomas account for about 11% of childhood cancers and about 14% of cancers in teenagers.

7. The majority of people are diagnosed when their sarcoma is about the size of a large tin of baked beans (10cm).
8. Sarcoma survival rates have been very gradually increasing over the last two decades in the UK. The five-year survival rate for sarcoma is 55%.

Achievements and Performance

Priority 1: Initiate change to raise awareness and improve standards of treatment and care

What we said we would do:

1. Increase the visibility of sarcoma and how it impacts on individuals and families so the public are familiar with sarcoma and its signs and symptoms.
2. Influence sarcoma health services so that sarcoma patients receive timely and high quality treatment and care, from diagnosis through to end of life care.

1. Increase Awareness - what we did:

Sarcoma Awareness Week 2019

The week proved to be the largest to date in terms of engagement and reach. The focus for the week was to formally introduce the charity's work on policy and campaigning, through 'Prioritise This', content including a survey that would gauge supporters' appetites for getting involved in this new area of the charity's work, knowing this would be an increasing ask in the coming years. Other activity included:

- Trialling a new ask for supporters to write to their local MP using dedicated postcards. We sent out more packs than anticipated (14), with supporters getting in touch to give updates as to what they said and what the response was from their MP or MSP. As the first ask of its kind, this uptake bodes well for the future, with several new MP leads created as a result of this.
- Engagement was highly encouraging, with Facebook engagement up by almost 450%, Twitter engagement by 129% and, similarly, Instagram was up 97%.
- Using the week as a vehicle to release the findings from the national awareness poll we had run through YouGov to establish levels of sarcoma awareness across the UK. This is now an annual occurrence.
- Interestingly, sarcoma awareness week went fully international in 2019, with contacts by patients and similar organisations from Vietnam, Poland, Australia, America, Italy and India. Some repurposed our message and content, whilst others referenced Sarcoma UK and awareness week directly.

The Loneliest Cancer

Working alongside Trinity PR, the charity's first ever national awareness campaign launched on Tuesday 26 November and was a success. As a large scale campaign, it ran well across all channels, including:

- Strong pickup from the media with 50 pieces of coverage across national papers the Daily Telegraph, Daily Mirror, Evening Standard and Daily Express and regional press, which centred on letters to the editor, and one piece of women's consumer magazine.
- A broadcast day which was picked up by 16 regional radio stations across the UK, and one additional piece in BBC Hereford and Worcester.
- One TV interview with Richard Davidson (Chief Executive) on ITV Wales News.
- Two advertorials in trade GP publications, which helped prompt more than 360 downloads of the newly updated GP diagnostic toolkits aimed at GPs and 43 direct referrals to the sarcoma UK website purely from this GP focussed activity.
- Huge increases in social media engagement. The Loneliest Cancer hashtag seemed to really resonate with supporters, and our Facebook posts in particular seemed to prompt a whole raft of people who never engage with the charity, to the forefront. Facebook engagement went up by 922%, Twitter up by 177% and Instagram up by 188% in the three-week period of the campaign.

The Loneliest Cancer report, the focus of the campaign, has been downloaded more than 700 times from the website, and was the focus of the charity's first ever Parliamentary drop-in event on 21 January 2020.

- The event gave MPs the chance to meet with Sarcoma UK to learn more about sarcoma and to learn about the findings of the report. We met with more than 20 MPs, including Jo Churchill MP, Parliamentary Under Secretary of State for Prevention, Public Health and Primary Care.
- This work was part of a wider public affairs programme, which saw meetings with MPs from across the political spectrum.

2. Influence health policy to improve sarcoma specialised services

Building a Policy Base

The creation of a new formal Policy and Public Affairs function meant that the charity was able to formalise and back up the policy positions on which it had been campaigning for many years, as well as work towards new priorities.

Policy Changes

- In July, NHS England launch the Service Specification for Sarcoma. Despite being delayed for so long, Sarcoma UK brought together the clinical community and held NHS England to task. The new commissioning document standardises sarcoma care, clarifying which patients need specialised surgery, and helping to ensure that patients get access to the best care.
- After many years of campaigning, the Royal College of Obstetrics and Gynaecology published consent advice and patient information for morcellation in collaboration with the Royal College of Radiologists, the Royal College of Pathologists, British Sarcoma Group, Sarcoma UK and the British Society for Gynaecological Endoscopy. This comes after several years of collaboration and consultation responses, and ensures that women considering morcellation as a treatment for fibroids are made aware of the likelihood of unexpected uterine sarcoma and the risk involved in morcellation.

Data

Sarcoma data has historically been poor. This year saw a proliferation in sarcoma data as a result of the work of Sarcoma UK:

- Impact of Sarcoma: National Sarcoma Survey 2020, a reiteration of the seminal 2015 edition, showed the thoughts of 1,117 patients and carers to give one of the largest datasets of the experience of sarcoma in the UK. This covered a range of topics including awareness, diagnosis, and information and support.
- Get Data Out, a programme from Public Health England to provide data on cancers in England, meant that several years of sarcoma data, including subtype prevalence and route to diagnosis, became available.
- Sarcoma UK partnered with Public Health England to run a national workshop to improving data collection in sarcoma centres. Despite the NHS Long Term Plan committing to 75% of cancers being diagnosed at stage I or II, this data is not readily available in sarcoma: in 2018, only 27% of sarcomas had their tumour, lymph nodes, and metastasis grades recorded. By standardising this coding and having Public Health England commit to working with NHS Trust Data Managers and IT teams, this data will help us to understand when sarcomas are diagnosed.

Other Influencing

- A number of new medicines were put forward for appraisal this year. Sarcoma UK represented the views of the sarcoma community for five new treatments. Two of these medicines, larotrectinib and entrectinib, are a step-change in cancer treatment through genomics, and have been commissioned through the Cancer Drugs Fund for eligible sarcoma patients.
- Sarcoma UK has also worked collaboratively with other cancer charities across a number of sector-wide policy initiatives. This includes being part of the One Cancer Voice initiative, which set out a manifesto for the cancer sector and held NHS England to account over cancer services during the COVID-19 pandemic. We also worked with other charities across improving early diagnosis, the Genomic Medicine Service, and highlighting priorities for children and young people with cancer.

Priority 2: Seek answers through research

What we said we would do:

1. Become £1 million per year investor in sarcoma research.
2. Invest in sarcoma researchers of the future.
3. Identify transformational 'blue skies' research.

1. Become £1 million per year investor in sarcoma research - what we did:

- In 2019/20, Sarcoma UK invested £922,699 (up 41% on the previous year) into high quality scientific research into sarcoma, bringing the total of our investment into sarcoma research to £3,404,396.
The 2018/19 investment funded 7 research grants.

Grants awarded in 2019/20

Clinical Research Awards

Focusing high intensity ultrasound on sarcoma

Dr Paul Lyon, University of Oxford

£119,934

High Intensity Focused Ultrasound is an exciting treatment method, capable of destroying a tumour by targeting it with focused ultrasound waves from outside the body. It is both non-invasive and uses no radiation. This exciting early phase study is looking at how High Intensity Focused Ultrasound can be applied to soft tissue sarcoma.

Managing the fear of sarcoma returning

Dr Rachel Taylor, University College London Hospitals NHS Foundation Trust

£80,389

A person's fear of their sarcoma returning can have a huge impact on their quality of life. This project will explore the nature of fear of recurrence in patients with sarcoma, leading to the development of an intervention to help patients manage this difficult issue. The project builds on previous work by the same research group, also funded by Sarcoma UK.

2. Invest in sarcoma researchers of the future – what we did:

- We awarded four PhD studentships to train and develop sarcoma research leaders of the future.

Investigating drug resistance in Alveolar Soft Part Sarcoma
Dr Robin Jones, Institute of Cancer Research
£120,000

This project utilises the clinical samples obtained from patients in the CASPS trial to investigate drug resistance in Alveolar Soft Part Sarcoma. The work will provide the basis for new clinical trials that will help doctors to personalise sarcoma treatment to individual patients. It will also provide new insights into how to overcome resistance to the drug cediranib in ASPS patients.

Developing new drugs for sarcoma
Dr David Mann, Imperial College London
£119,873

Cancer cells develop multiple mechanisms to escape the normal controls that stop excessive cell division. One of these mechanisms involves increased production of proteins including Mcl1. This project involves developing small molecule chemicals to inhibit the function of Mcl1 and thereby re-instate the sensitivity of cancer cells to death. It is hoped that the combination of Mcl1 inhibitors with other chemotherapeutic agents that promote death will give very strong and robust responses leading to selective killing of sarcoma cells.

Targeting a cancer 'supercontroller' in Ewing's Sarcoma
Professor Susan Burchill, University of Leeds
£116,374

In Ewing's sarcoma, some cells become activated, causing the Ewing's cells to grow and divide out of control. This PhD project is investigating ways to turn off a protein called c-MYC, which regulates this process. Changing the expression of the c-MYC protein could provide tools to predict exploited to develop more personalised treatment in the future.

Targeting cancer cells while they are vulnerable to breakage
Professor Anderson Ryan, University of Oxford
£116,545

Cancer cells grow in an uncontrolled manner, dividing and growing without fully duplicating their genetic material. This leaves them vulnerable to breakage in a way that a normal cell is not. This PhD project is looking at ways to exploit this vulnerability in osteosarcoma cells, by using drugs that increase the instability in these cancer cells and cause them to die.

3. Identify transformational 'blue skies' research – what we did:

- In 2018, we launched our genomics research programme, aiming to bring together the best minds and the latest technologies in sarcoma research, to use data from the 100,000 Genomes Project to advance our understanding of sarcoma. 2019 marked our second major research award in genomics, bringing our total investment to £500,000.

Sarcoma UK Genomics Research Programme

A genomic approach to unlocking the secrets of sarcoma

Professor Andrew Beggs, University of Birmingham

£249,584

Professor Beggs and his team now hope to build on the work already conducted through the 100,000 genomes project to gather much more detailed data from the sarcoma samples by analysing the faults in single cells within tumours. Taking a focus on soft tissue sarcoma, the team will analyse the proteins being produced in cells and the level of gene activity, to compare between people with sarcoma and people who don't have sarcoma. The team plan to combine this information to provide a high precision map of what is going wrong, helping them to unlock the secrets of sarcoma.

From this data, Professor Beggs hopes to answer a very pressing question – why don't sarcomas respond well to cancer immunotherapies? Understanding this could mean that future immunotherapies could be developed that are much more effective for people with sarcoma.

We continued to fund previous research commitments – see sarcoma.org.uk for details.

We continue to monitor our funded research portfolio; in 2019/20 our funded research had the following outputs:

- 15 oral presentations at UK and international scientific meetings and conferences;
- 4 poster presentations at UK and international scientific meetings and conferences, one of which was awarded best Young Investigators Award at the 2018 Musculoskeletal Tumour Society;
- 14 academic publications in peer reviewed journals; and
- 4 clinical workshops held

Priority 3: Support the sarcoma community and provide information

What we said we would do:

1. Become a sarcoma expert information provider of choice.
2. Be the first port of call for support.
3. Work in partnership with others.

1. Sarcoma expert information provider of choice – what we did:

- We distributed 3,112 patient information booklets and factsheets to specialist centres, treatment centres and information centres. Healthcare Professionals continue to be the main audience for our printed material to give out to patients. However, we are seeing a decrease of 40% in overall mail outs with healthcare professionals increasingly using downloadable resources too. Online downloads remain steady with just over 14,000 downloads this year.
- We have produced a number of new resources this year including, factsheets on DSFP, and Phyllodes of the breast, a booklet on Understanding Head and Neck sarcoma, and advice for families and carers on supporting a loved one diagnosed with sarcoma.

2. First port of call for support - what we did:

- The Support Line was open for 25 hours a week from 15 July 2019, an increase of 5 hours a week, Monday-Friday 10am - 3pm, responding to questions from patients, family members, friends and health professionals by phone and email.
- From 1 April 2019 to 31 March 2020, the Support Line had 2,863 queries from 751 people - an increase of 73% of queries and an increase of 43% on the number of people using our service. There was an average monthly increase of 74.45% in contacts.
- In November 2019 we launched the new Text service where people who wanted to contact the support line team could now do that via text message. Up to 31 March 2020 the team had 83 text conversations with 68 individuals. These conversations total 309 individual text messages.
- March 2020 saw the lockdown due to the COVID-19 pandemic. In the two weeks prior to lockdown the support line team saw an increase of contacts to the team of 47.7%, and an increase of 81% of individuals. As of 18 March 2020 the Support Line team were rostered so that 2 members of the team were available each day to answer any questions that came in to the team.

- In September 2019 we hosted our first Support Group Leader network day where we equipped leaders with knowledge and skills in providing practical and emotional support, both for themselves and others. It also provided group leaders with the opportunity to network in person for the first time.
- We supported the relaunch of the West Midlands and North of England support groups.
- We created support group marketing materials for group leaders' use to promote their groups.
- We set up a peer support network via a group email so that leaders can contact each other directly.
- We initiated a new quarterly support group leader bulletin, which includes content specifically tailored to support group leaders.
- We produced and published a set of support group leader guidelines aimed at existing and new support group leaders, in collaboration with existing support group leaders.
- We provided funding to the Desmoid United support group to host the first Desmoid patient conference which we attended to provide support and information to desmoid patients.
- In March we hosted a question and answer session about Covid-19 for support group leaders to clarify government guidelines and what this meant for sarcoma patients.
- We provided one to one coaching and advice to support group leaders in using Zoom videoconferencing, which subsequently enabled them to start hosting virtual support group meetings.

3. Partnership working - what we did:

- This year saw the launch of our inaugural Tricia Moate Award. We had nine applications from different backgrounds. The winners were Lucy Dean, physiotherapist from the Royal Marsden Hospital and Charlotte Harvey-Wright, radiographer from Cambridge.
- In October 2019 we ran a peer support event for young people with sarcoma in collaboration with Trekstock.
- The Information and Support Team have been working with Ovacome (an ovarian cancer charity). We share experiences and best practice in order to best improve our services.
- We have built relationships with age specific charities: Shine Cancer Support, Teenage Cancer Trust and CLIC Sargent. All three offer very different services to Sarcoma UK; however, where we add value is our knowledge and expertise in sarcoma. We are identifying ways in which we can work more closely together; however, all agree we should be promoting each other's services where appropriate.
- In October we ran a peer support event in collaboration with Trekstock aimed at 18-30 year olds with sarcoma. The event was attended by 10 sarcoma patients, most brought a plus one. The day was well evaluated with themes including diet, yoga, life coaching and fitness being well received.

Priority 4: Build a strong charity

Our achievements are only possible because of the energy and generosity of our fundraisers and donors. Our diverse philanthropic community includes patients, their family and friends, health professionals, charitable trusts and businesses. Their enthusiasm, loyalty and belief in Sarcoma UK are vital to ensure people affected by sarcoma have the support they need, and sarcoma researchers continue to move closer to finding effective treatments. In 2019/20, our income was £2,709,071. We express our deepest gratitude to everyone who has made a donation or helped to raise funds this year.

Highlights of the year included:

- The London Marathon continues to be our successful flagship fundraising event, with 77 joining the team and 62 runners completing the marathon, raising £234,508 before gift aid. We have continued to build upon our Team Sarcoma experience by inviting them to join an inclusive closed Facebook Group where we encourage our runners to interact with us as well as each other. The Group attracted 62 members, meaning under 20 of the team chose not to join. We also expanded our cheer stations this year and decided to meet our runners and families at the finish line, so we could walk them to our After Party venue. This was hugely appreciated by the runners, and it meant more of the team came compared to previous years.
- To increase our fundraising offerings in light of the postponement of fundraising events such as the London Marathon we have developed new community packages for our supporters to sign up to including the Virtual Runner 500km event. This challenge runs across 2020 and our supporters can run, walk, cycle or swim the 500km distance across the year and receive a medal for their achievements. This has worked well for our supporters to complete in their own time no matter their abilities.
- With the growth of our fundraising team we have been able to introduce increased activity in new fundraising streams and continue to provide the gold star service our supporters expect and deserve.
- We concentrated on building our Trust and Foundations offering. This year we piloted approaches to Trusts and Foundations that increased our likelihood of receiving a gift. We looked to our network of engaged supporters to help us secure meetings, produce cover letters and tailor our reports and applications. Our new way of looking at Trusts and Foundations was successful and we welcome any supporters' input or knowledge on Trusts and Foundations they would like us to apply to.
- To support our major givers and relationships with our incredibly special supporters, we held a successful series of events. This started in June with a tight turnaround of an event at 10 Downing Street where we launched our Genomics programme. This resulted in key engagement and donations of over £30,000. We held our first carol concert at St Paul's in Covent Garden. This was a highly successful event with entertainment and readings from celebrities including Madeline Bell, Linda Robson, Robert Powell, Sandra Dickinson and Richard Arnold. The event was hosted by Canon Roger Royle and sold out within two weeks. In association with this event, we ran a successful name a star campaign in honour of a loved one's battle with sarcoma. Finally, we developed a Gala committee and with our support, they held the

first Sarcoma UK Glitter Ball on 7th March 2020. This was attended by over 300 guests and attracted money can't buy auction prizes from Hugh Grant and Eddie Redmayne.



- Sarcoma UK would like to thank the Chris Martin Fellowship, who held the annual quiz, which raised a record £38,000 this year and helped establish a Genomics Development Board to support us in raising restricted funds for our genomics programme.
- We continue our wonderful partnership with The Analyst, our longest corporate partner, through away days and regular updates. The relationship with The Analyst is growing with additional funding and other support.
- We launched a successful legacy campaign this year. Since the launch we have been notified by several individuals that they will be leaving a legacy to Sarcoma UK in their wills, which could result in over £350,000.
- To increase our engagement with our supporters and fundraisers, we set up a new public Facebook page called 'Team Sarcoma: Community' for all things to do with fundraising in our sarcoma community. We have shared our fundraising tips, updates on upcoming activities and shared pictures and videos from our fundraiser's activities.
- In 2019 we received incredible support from fundraiser Daisy Ellis while she was going through treatment for sarcoma. We also supported many of her family and friends through their activities in Daisy's honour.
- Since launching the volunteering programme in 2018, we have received a large number of registrations from our supporters across the UK looking to actively help the charity as sports therapist volunteers, cheer station volunteers or charity representative volunteers. This has meant we have been able to support and attend at even more fundraising events and challenge events than previously.

At Sarcoma UK we aim for best practice in all our fundraising activities. Our fundraising approach is to build long-term, meaningful relationships with donors and fundraisers based on transparency, respect and the clear demonstration of the value of their involvement. We are aware that some supporters may be vulnerable or go through periods of vulnerability, and have documented measures in place to help identify and protect vulnerable people who are in contact with the charity.

We have been registered with the Fundraising Regulator since its inception and comply with the Code of Fundraising Practice. We have a complaints procedure where our donors can register complaints. We have received no complaints in the year through this channel. We do not use third-party agencies to fundraise on our behalf.

The Finance and Operations team achieved the following:

- Ensured that the whole organisation was GDPR compliant.
- Oversaw the smooth transition to remote working for the whole team when the COVID-19 pandemic hit.
- Updated the Staff Handbook and wrote and updated a number of policies and procedures.
- Won the Third Sector's Finance team of the year award for 2019.



The above activities include 16% support costs and 2% governance costs, which have been re-allocated to each activity (see notes to financial statements)

Future Plans

In the coming year we will continue on our path towards achieving the objectives outlined in our refreshed strategy to 2021.

1. Research

- Become £1 million per year investor in sarcoma research.
- Invest in sarcoma researchers of the future.
- Identify transformational 'blue skies' research.

2. Information and Support

- Sarcoma expert information provider of choice.
- First port of call for support.
- Partnership working with appropriate organisations.

3. Awareness/Campaigning

- Develop a strong national voice.
- Influence and change national policy to benefit people affected by sarcoma through issue-based campaigns.
- Increase public awareness of sarcoma through higher profile and targeted campaigns.

Specifically, in 2020-21 we aim to:

- Increase the number of patients and their families we support. This is a particularly anxious time for sarcoma patients as there is much uncertainty about their risk, treatment and care and we will continue to grow our support to anyone affected by sarcoma.
- Protect the long term sustainability of the organisation by diversifying our income and building strong and lasting relationships with our supporters. This will include creating more digital or virtual fundraising offers, investing in stewardship and continuing to address the imbalance in our fundraising portfolio.
- Invest in excellent research into sarcoma.
- Influence national and regional policy to benefit people affected by sarcoma.
- Develop an ambitious strategy for the organisation that is shaped by patients and the wider sarcoma community.

We will do that by:

- Raising at least £1.690m.
- Raising awareness of sarcoma amongst the public and with healthcare professionals.
- Improving how we steward every donor to ensure they feel supported and regularly updated about the impact their funding is having.

- Articulating how we believe the healthcare policy environment can change to improve the outcomes and experience for sarcoma patients.

The impact of COVID-19 on Sarcoma UK's work

Although the impact of the COVID-19 pandemic was not felt in the UK until the final month of the financial year, it has had a profound effect on our operations and outlook.

We responded quickly as a charity in three ways:

1. Firstly we expanded the resource on our Support Line so that we could handle the huge increase in calls and contacts from anxious patients and their families. People were worried about their risk, about treatment being interrupted and how safe hospitals were. We provided tailored information and created videos alongside working in partnership with NHS England and the One Cancer Voice coalition of charities. Subsequently, as it became apparent that cancers were going undiagnosed as a result of the pandemic, we actively encouraged people who were worried that they had sarcoma symptoms to visit their GP and ask to be referred.
2. We quickly trialled and then implemented remote working for all staff members so that we could all work productively from home. We changed our processes and ways of working so that staff felt engaged and supported during the difficult early months.
3. We pivoted our fundraising away from cancelled events and community activity towards online fundraising and Trusts and Major Gifts. In the early weeks this involved trialling and testing a number of digital fundraising activities, but this has since become more targeted and focussed as it has become clear what appeals to our supporters.

We have regularly and consistently spoken to the staff team to ensure that morale is high and they feel supported and engaged. In a recent survey, 100% of our staff felt that the organisation had responded well to the pandemic and felt supported by their line manager.

The impact of the pandemic on our income is dramatic, in line with what other charities are experiencing and reporting. Initially we feared that the coming year would see a decrease of up to 35% in income. We now believe it could be even higher. We regular report to trustees on our income and expenditure and, in line with our reserves policy, we have decreased our expenditure this year and are forecasting a greater use of our free reserves and a deficit at the end of the financial year. We have taken advantage of the Government's Job Retention Scheme, some staff have taken voluntary temporary pay cuts and we have cut both our research expenditure and discretionary funding on projects.

Inevitably our impact in 2020-21 will be down on what we achieved in 2019-20 but we are doing all that we can to ensure that our income, expenditure and impact will bounce back and be greater in 2021-22. We believe the actions we are taking in 2020 will help us emerge from the current pandemic as a stronger and more resilient organisation.

Governance, Structure and Management

Legal Entity

Sarcoma UK is a charity registered in England and Wales with the Charity Commission on 17 January 2011, and registered as a charity in Scotland on 12 September 2013. Its governing

documents are its memorandum and articles of association. Sarcoma UK is also a company limited by guarantee incorporated with Companies House on 10 January 2011.

Sarcoma UK is sole corporate Trustee of former charity The Sarcoma Trust.

Charitable Objectives

The objectives of the charity are: to promote and protect the physical and mental health of patients with bone and soft tissue sarcomas in the United Kingdom through the provision of information, support, education and practical advice to them, their families and their carers; the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; to advance the education of the general public in all areas relating to sarcoma.

Board of Trustees 2019/20

Glyn Wilmshurst –Chair

Glyn co-founded the communications agency Touchline, which produces the publications, websites and branding of several governments as well as various international arts, trade, travel and sports organisations. Glyn was diagnosed with a myxoid liposarcoma in December 2010.

Sarah Conneally

Sarah is former Head of Events & Visits at 10 Downing Street, having worked for both David Cameron and Theresa May. Sarah was a colleague of Chris Martin at 10 Downing Street and she led their working group during our charity of the year partnership in 2016. Sarah is now a Director at the newly formed Commonwealth Summit Unit, part of the Cabinet Office.

Andy Eckles – Trustee with special interest in finance

Andy has 30 years' experience in finance, as both an auditor and currently as Group Financial Controller at Huntswood, a company that provides specialist resourcing and consultancy services. Andy's son, Tom, passed away from Ewing's sarcoma in September 2015.

Professor Rob Grimer

Rob is a (retired) Professor of Orthopaedic Oncology at the Royal Orthopaedic Hospital, Birmingham. During his long career in sarcoma, he helped pioneer the use of extendable prostheses and new surgical techniques such as irradiation and re-implantation of bone to treat sarcoma. He is a founding member of the British Sarcoma Group.

Ian Hughes

Ian was the owner of SILO Consulting Ltd, based in York. Ian was diagnosed with leiomyosarcoma in 2010 and sadly passed away in January 2020. Ian was extremely committed and dedicated to Sarcoma UK over the years and will be greatly missed.

Professor Ian Judson

Ian has been treating patients with sarcoma for 25 years as Head of the Sarcoma Unit at the Royal Marsden until his retirement in 2016. He has conducted many clinical trials in this area, and was a founder member of the British Sarcoma Group, and President until 2015.

Louisa Nicoll

Louisa is a nurse with extensive experience in the delivery of oncological and specialist palliative care services. She is currently Ward Manager at a Sue Ryder hospice in Henley-on-Thames. Louisa's husband was diagnosed with high grade osteosarcoma in March 2016.

Sam Patton

Sam Patton is the Director of Orthopaedics & Consultant Orthopaedic Surgeon at the Royal Infirmary of Edinburgh. Sam has a long history of sarcoma practice and has served as a panel member on our Research Advisory Committee. Among his relevant experience are positions including Oncology Editor for The Bone & Joint Journal (the premier UK based orthopaedic journal) and Lead Clinician, Scottish Sarcoma Network in 2007-2013.

Sharon Reid

Sharon is a former Executive Director and Chief Operating Officer at Edelman, the world's largest PR agency, and has worked in communications for the last 18 years.

Isla Robinson

Isla Robinson is a freelance Marketing Consultant (Director level) with over 15 years' experience of local and global marketing, including as a lead member of the team for Campari UK. Isla brings her professional expertise to the Board alongside first-hand experience of Ewing's sarcoma with which she was diagnosed in 2011. This was when Isla first discovered Sarcoma UK, and she has since found the charity to be a 'key source' of reliable information.

Anjula Thompson

Anjula qualified as a Solicitor in 1993. She worked in private practice for 10 years and thereafter as a legal officer in the voluntary sector before taking up her current role, in 2005 as a Deputy District Judge, adjudicating in Civil and family cases. Anjula is the wife of Sarcoma UK trustee Dave Thompson who sadly passed away in 2016.

Johanne Vass

Jo is a Sarcoma Advanced Nurse Practitioner, the lead for sarcoma nursing services and a key member of the South Wales Sarcoma Multi-Disciplinary Team. She was the first sarcoma specialist nurse to be appointed in South Wales in 2012.

Dr Jeff White

Jeff is a consultant medical oncologist working in sarcoma at the Beatson West of Scotland Cancer Centre, and former National Lead Clinician for the Scottish Sarcoma Network.

Sam Whittam

Sam is a barrister working principally in the area of child protection and was called to the bar in 1995. In 2009, Sam lost her friend to sarcoma.

Russ Wilson

Russ is currently a Partner at Hall & Partners, one of the UK's leading Brand Strategy consultancies. Russ has a very personal experience of sarcoma, having had an osteosarcoma removed from his leg when he was in his 20s.

In October 2017 the Board agreed to formally sign up to the Charity Governance Code, to manage and take responsibility for Trustee governance. It formed two committees, the Nominations and Human Resources (NHR) Committee and the Governance, Risk and Finance (GRF) Committee.

Nominations and Human Resources Committee (NHR)

Responsible for HR and staffing issues, including staff remuneration. Responsibility for the renewal of tenure, recruitment and appointment of trustees is also delegated to the **Nominations and Human Resources Committee** who make recommendations to the Board of Trustees.

Members 2019/20:

- Sam Whittam (Chair)
- Louisa Nicoll
- Jeff White
- Sharon Reid

Governance, Risk and Finance Committee (GRF)

Responsible for overseeing governance, organisational risk and working with the Senior Management Team on finance. The **Governance, Risk and Finance Committee** make recommendations to the Board of Trustees.

Members 2019/20:

- Ian Judson (Chair)
- Andy Eckles
- Anjula Thompson
- Johanne Vass

Trustee Appointment and Induction

Sarcoma UK places a high value on having an informed and skilled Board of Trustees which guides the charity to achieve its ambitious goals.

Trustees serve a three-year term, after which they are eligible for re-election for a further three years.

New trustees are recruited in various ways, according to the skills sought by the Board. Vacancies are advertised in national charity media, through professional networks and via the charity's website and networks. Potential trustees are invited to submit a formal application and attend an interview with the Nomination and Human Resources Committee.

All trustees receive the Trustee Handbook, setting out the role and responsibilities of

Sarcoma UK trustees, including the charity's policies and procedures relating to governance. A Register of Trustees' Interests is in place and updated annually.

All new trustees receive the governing document, strategy and business plan, published accounts and minutes of previous Board of Trustee meetings, Trustee Handbook, as well as Charity Commission guidance on effective governance. A formal induction programme is in place, where trustees spend time with the Chief Executive and the Senior Management Team. Trustees are subscribed to Governance publication and are encouraged to attend training and other events for charity trustees.

Organisational Structure

The Board of Trustees sets the strategic direction of Sarcoma UK and approves the main policies of the charity. It appoints and directs the Chief Executive, monitors performance and identifies and manages the major risks facing the charity. The Board meets four times a year.

The Board delegates responsibility for the running of the charity to the Chief Executive with clearly communicated and recorded executive limits. The Chief Executive is responsible and accountable for achieving Sarcoma UK's strategic objectives and delivering the annual business plan. A Senior Management Team is in place to support the Chief Executive, providing leadership across key areas of the charity's work, and ensuring delivery of the charity's day-to-day work.

Sarcoma UK's Senior Management Team in 2019/20 consisted of:

- Chief Executive
- Communications Director
- Director of Finance and Resources (Head of Finance and Resources during period of maternity leave)
- Director of Fundraising
- Director of Research and Policy
- Director of Information and Support

Sarcoma UK has a policy for reviewing staff salaries, set out in the Staff Handbook. Staff salaries are reviewed annually by the Board of Trustees Nominations and Human Resources Committee, on behalf of the Board of Trustees, and benchmarked against voluntary sector pay surveys and inflation. The remuneration of senior management is covered under this policy.

The total number of staff employed at 31 March 2019 was 22 (including 7 part-time). The trustees are grateful to the staff team for the outstanding work they do on behalf of people affected by sarcoma.

Volunteers

The trustees recognise the valuable contribution made by volunteers to Sarcoma UK and wish to record their gratitude for this commitment. These include: members of Sarcoma UK's Research Advisory Committee; sarcoma support group leaders; Sarcoma UK's

Information Review Panel; Sarcoma UK's Medical Advisory Group, individuals and families who have provided their stories for use as case studies; everyone who has undertaken fundraising and awareness-raising in their communities; everyone who has set up information stands or cheering stations at events; and everyone who has supported Sarcoma UK at events and activities throughout the year. In accordance with accepted practice, no amounts are included in the financial statements to reflect the value of work undertaken by volunteers.

Risk Assessment

To manage risk effectively, Sarcoma UK uses a risk assessment model. The model sets out the processes for identifying major strategic risks, assessing their likely impact and, where appropriate, the measures that need to be implemented to mitigate the risks. These risks are regularly reviewed by the Senior Management Team and the Trustee Governance Risk and Finance Committee.

In our risk assessment model, risks are categorised under the following headings: Governance, Financial, Operational, Environmental and External Factors, Compliance Risk, and Charitable Objectives.

The most significant current risk to the charity has been identified as the impact of the external environment on fundraising, in particular:

1. Change to fundraising regulations.
2. Public confidence in charities.
3. Uncertainty around Britain's withdrawal from the EU and the possible economic impact.

To manage this risk, the following actions will be incorporated into the risk model:

1. Investment into new fundraising streams to spread the risk and establish greater diversity in fundraising sources and provide a more balanced income portfolio.
2. Continue to be transparent in our practices demonstrating our activities and impact.
3. Robust monitoring of monthly management accounts to identify changes in income patterns as early as possible.

The risk model has been reviewed by the trustees and they are satisfied that appropriate systems are in place to mitigate major risks.

Grant Making Policy

Our research grants programme for sarcoma involves annual calls for proposals. These calls are open competition and publicised on our website and to the UK sarcoma research community, in particular research active sarcoma clinicians and UK Higher Education Institutes.

Applications submitted undergo a rigorous external peer review process to identify the best quality sarcoma research projects in centres of excellence across the UK. Our Research Advisory Committee considers all peer reviews and makes recommendations for funding to the Board of Trustees, who approve the final grants to be awarded.

Sarcoma UK is a member of the Association of Medical Research Charities (AMRC) and is fully compliant with their practices. Our Principle of Peer Review Policy is published and all applicants are made aware of it. We publish our Conflicts of Interest policy, whereby all members of the Research Advisory Committee are required to provide an annual declaration of potential conflicts of interest. The policy also sets out the conditions for automatic exclusion from participation in funding decisions for members who have conflicts of interest, and this policy is implemented rigorously at meetings.

Our research strategy states that no area of research is given greater priority over any other within a call. We always award on the basis of the scientific quality of the proposed studies. Clinical research projects must be patient focused. We will support both people and projects, and will provide funding for pump-priming research to support the development of ideas. We wish to increase the sum total of sarcoma research in the UK and remain flexible in our approach towards funding and research partnerships.

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

Working with Others

Sarcoma UK recognises that progress towards our goals is maximised when working collaboratively with others who share an interest in improving the lives of people affected by sarcoma. As the only UK charity focusing on all types of sarcoma, we aim to work collaboratively with the whole sarcoma community to achieve our vision for the future. In 2019/20, Sarcoma UK had collaborations with: the Association of Medical Research Charities (AMRC); BMJ Learning; Boom Foundation (Northern Ireland); British Sarcoma Group; Cancer 52; National Cancer Registry and Analysis Service (NCRAS), Welsh Cancer Intelligence and Surveillance Unit, Information Services Division of the NHS National Services Scotland, N. Ireland Cancer Registry, GIST Support UK; National Cancer Research Institute (NCRI) sarcoma clinical studies group; NCRI James Lind Alliance Priority Setting Partnership – Living With and Beyond Cancer steering group; National Institute of Health and Care Excellence (NICE); National Sarcoma Forum (of specialist nurses); NHS England; Public Health England, Sarcoma Patients EuroNet; the Scottish Sarcoma Network; and the network of sarcoma specialist centres – bone and soft tissue – in England, Wales and Northern Ireland.

Financial Review

Income

Sarcoma UK has made excellent progress against its objectives for the year, successfully raising £2,709,071, an increase of 45% from the previous year (2019: £1,863,535), which exceeded our income budget for the year. This is primarily due to an increase in major gifts (212%), trusts and foundations (188%), corporate (186%), and general donations (8%).

The trustees wish to thank all donors for their invaluable support during the year, which is helping Sarcoma UK transform the lives of everyone affected by sarcoma.

Expenditure

Total expenditure increased to £2,485,626 (2019: £1,851,808), an increase of 34% mainly as a result of:

- Increasing grants made by £249,950 as part of the strategy to be a £1 million research funder by 2020-21.
- An increase in staff costs of £186,795, which was due to full year costs of new posts recruited in 2018/19 and new posts in the year.
- An increase in event costs of £69,361 as we held our first ever Carol Service and Glitter Ball.
- An increase in our awareness and campaigning projects of £52,640 through the creation of a new formal Policy and Public Affairs function.

Sarcoma monitors spending closely, employing the use of financial management and budgetary controls across the charity and expenditure on our charitable activities remained high at 74% of total expenditure.

We strive to keep the costs of raising money to a minimum. There has been an increase of 30% in the cost of raising funds, which has directly resulted in an increase in our level of income. This year for every £1 spent on fundraising £4.11 was raised. This has increased from the prior year as we have seen a significant increase in our income.

A surplus of £223,445 (2019: £11,727) was made this year and increases total charity funds to £1,402,164 (2019: £1,178,719), of which £ (34,990) are restricted as we made a research grant in 18/19 for which we will receive funding from the McAlpine Trust over three years. The reserves policy is discussed below.

Reserves Policy

Sarcoma UK revised its reserves policy during 2020. The Board of Trustees now aim to maintain reserves at a level which equates to approximately nine months of operational costs including budgeted salary, rent and support costs. This is approximately £750,000 for the forthcoming year.

The total funds of the charity at 31 March 2020 were £1,402,164 of which £ (34,990) are restricted. This leaves a balance of £1,437,154 as unrestricted funds. The trustees have agreed to designate £100,000 of these unrestricted funds to our core research costs and £100,000 to our information and support service in 2020/21, £13,289 are tied up as fixed assets leaving a balance of £1,223,865, which exceeds the level required by the reserves policy. Remaining funds of £473,865 will be applied to furthering our mission to ensure everyone affected by sarcoma receives the best treatment, care, information and support available and to create the treatments of the future.

The reserves policy including designation of funds will be reviewed in 2021 to ensure it is adequate for the charity's future operational needs.

Statement of responsibilities of the trustees

The trustees (who are also directors of Sarcoma UK for the purposes of company law) are responsible for preparing the trustees' annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting Standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The total number of such guarantees at 31 March 2019 was 12 (2018:12). The trustees are members of the charity but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Auditor

Sayer Vincent LLP was re-appointed as the charitable company's auditor during the year and has expressed its willingness to continue in that capacity.

The trustees' annual report has been approved by the trustees on 6 October 2020 and signed on their behalf by

Glyn Wilmshurst
Chair of Trustees

Acknowledgements

Patron Richard Whitehead MBE
Founder Roger Wilson CBE

Research Advisory Committee

Professor Jeremy Whelan (Chair), Professor of Cancer Medicine, University College London.

Professor Andrew Beggs, Reader in Cancer Genetics & Surgery, University of Birmingham.

Dr Sam Behjati, Group Leader at the Wellcome Sanger Institute. Consultant Paediatric Oncologist, Addenbrooke's Hospital, Cambridge.

Dr Sara Booth, Honorary Consultant, Associate Lecturer, University of Cambridge
Honorary Senior Lecturer at the Department of Palliative Care and Policy, King's College London.

Dr Bernadette Brennan, Consultant Paediatric Oncologist, Royal Manchester Children's Hospital.

Professor Susan Burchill, Professor of Adolescent and Paediatric Cancer Research, Leeds Institute of Cancer and Pathology, University of Leeds.

Dr Quentin Campbell Hewson, Consultant Paediatric Oncologist, Great North Children's Hospital in Newcastle upon Tyne.

Dr Louise Carter, Senior Clinical Lecturer in Experimental Cancer Medicine, University of Manchester.

Mr Paul Cool, Consultant Orthopaedic & Oncological Surgeon, The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry.

Mr Anant Desai, Consultant General Surgeon, Queen Elizabeth Hospital, Birmingham.

Professor Adrienne Flanagan, Professor of Musculoskeletal Pathology, University College London. Consultant Pathologist/Clinical Lead, Royal National Orthopaedic Hospital

Mr Craig Gerrand, Consultant Orthopaedic Surgeon, Royal National Orthopaedic Hospital.

Dr Paul Huang, Team Leader, Division of Molecular Pathology, Institute of Cancer Research.

Sarcoma UK
Acknowledgements
For the year ended 31 March 2020

Professor Ted Hupp, Principal Investigator and Professor of Cancer Research, University of Edinburgh.

Dr Christina Messiou, Consultant Radiologist, The Royal Marsden Hospital and Honorary Faculty at The Institute of Cancer Research.

Dr Sophie Postel-Vinay, Physician Scientist, Drug Development Department and U981 INSERM research unit, Gustave Roussy Cancer Campus.

Dr Karen Sisley, Senior Lecturer, University of Sheffield.

Dr James Spicer, Consultant in Medical Oncology, Guy's and St Thomas' Hospitals Co-lead of the King's Experimental Cancer Medicine Centre, King's College London.

Dr Sandra Strauss, Consultant Medical Oncologist, University College Hospitals London.

Professor Galina Velikova, Chair of Psychosocial and Medical Oncology, University of Leeds.

Dr Jayne Wood, Consultant in Palliative Medicine and Clinical Lead, Royal Marsden and Royal Brompton Hospitals London.

We are deeply grateful to all those that have supported us during the year with special thanks to:

Aesica Pharmaceuticals Ltd
Adam Jones Fund
Amy Westlake Fund
Ascot Underwriting Limited
Barclays Bank PLC
BDO LLP
Bernays Charitable Trust
Birmingham Hospital Saturday Fund Medical Charity
CBRE Charitable Trust
Charley's Fund
Chris Martin Fund
Daisy Ellis
Dave Thompson Fund
Derek Watkins Fund 007
Diageo
Digswell Park Sports Association
Eventbrite Inc
Fortis in Arduis
GeeWizz Charitable Trust
Google Inc
Guy Butler Ltd

Sarcoma UK
Acknowledgements
For the year ended 31 March 2020

HSBC Bank PLC
Holt Doctors
Hope's Fund
Huntswood Limited
James Hessey Fund
Jessica's Sarcoma Awareness
Lee Shields Memorial Fund
Leigh Haskin Fund
LinkedIn
Luis' Legacy
Maidenhead Rugby Tigers
Marks and Spencer Fosse Park
Omidyar Network UK Ltd
Parvinder Sawhney Fund
Peter Thompson Fund
Richard Sumner Fund
Roy John Watson Charitable Trust
Roy Thompson Charitable Trust
Rye Bay Capital LLP
Sandie's Stars Fund
Sarcoma UK Genomics Development Board
Sarcoma UK Glitter Ball Gala Committee
Sayako Grace Robinson Fund
Steph Darling Fund
Subsea 7
Terry Allison Tribute Fund
The Alice Ellen Cooper-Dean Charitable Foundation
The Analyst
The Boom Foundation
The Cissie Rosefield Charitable Trust
The Diana & Allan Morgenthau Charitable Trust
The Duke of Cumberland
The Hospital Saturday Fund
The Illumina Foundation
The Jacob Maloy Osteosarcoma Trust
The Kitty and Daniel Nabarro Charitable Trust
The Lass Charitable Trust
The Mason Le Page Charitable Trust
The Mistra Trust
The Morgan & Sarah Charitable Trust
The Northwood Charitable Trust (DC Thomson Charitable Trust)
The Paul Cottingham Trust
The Rachel Cullen Foundation
The Robert McAlpine Foundation
The Sylvia and Colin Shepherd Charitable Trust
The TL Trust

**Sarcoma UK
Acknowledgements
For the year ended 31 March 2020**

The Will Charitable Trust
The Wilmcote Charitrust
The Woodroffe Benton Foundation
Three
Tom Eckles Fund
Tom E. Whyman
Tom's Legacy Fund
Tom McMahon Fund
TUI Business Transformation.
Ulegend Fund
Whitaker Charitable Trust
Workday Inc

Individuals who have provided professional support

Mark Gould (Director, The Systems Management Company) has provided valuable professional support and advice to Sarcoma UK on a pro-bono basis.

A huge thank-you to all our supporters.

Opinion

We have audited the financial statements of Sarcoma UK (the 'charitable company') for the year ended 31 March 2020 which comprise the statement of financial activities, balance sheet, statement of cash flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- Give a true and fair view of the state of the charitable company's affairs as at 31 March 2020 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended.
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice.
- Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- The trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- The trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not

express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements.
- The trustees' annual report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- Adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- The financial statements are not in agreement with the accounting records and returns; or
- Certain disclosures of trustees' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit; or
- The trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in
- preparing the trustees' annual report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities set out in the trustees' annual report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the

trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Noelia Serrano (Senior statutory auditor)

16 October 2020

for and on behalf of Sayer Vincent LLP, Statutory Auditor

Invicta House, 108-114 Golden Lane, LONDON, EC1Y 0TL

Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006

Sarcoma UK

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2020

	Note	Unrestricted £	Restricted £	2020 Total £	Unrestricted £	Restricted £	2019 Total £
Income from:							
Donations and legacies	2	1,812,712	887,039	2,699,751	1,594,194	263,981	1,858,175
Investments		9,320	-	9,320	5,360	-	5,360
Total income		1,822,032	887,039	2,709,071	1,599,554	263,981	1,863,535
Expenditure on:							
Raising funds	3	656,002	543	656,545	504,409	517	504,926
Charitable activities							
Research	3	318,112	795,882	1,113,994	483,058	322,815	805,873
Information and support	3	312,586	30,302	342,888	276,158	12,052	288,210
Awareness, campaigns and education	3	345,192	27,007	372,199	252,505	294	252,799
Total expenditure		1,631,892	853,734	2,485,626	1,516,130	335,678	1,851,808
Net income / (expenditure) and net movement in funds for the year	5	190,140	33,305	223,445	83,424	(71,697)	11,727
Reconciliation of funds:							
Total funds brought forward		1,247,014	(68,295)	1,178,719	1,163,590	3,402	1,166,992
Total funds carried forward		1,437,154	(34,990)	1,402,164	1,247,014	(68,295)	1,178,719

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 16 to the financial statements.

Sarcoma UK

Balance sheet

Company no. 7487432

As at 31 March 2020

	Note	£	2020 £	£	2019 £
Fixed assets:					
Tangible assets	10		13,289		16,474
			13,289		16,474
Current assets:					
Debtors	11	422,189		549,148	
Short term deposits		215,967		213,041	
Cash and cash equivalents		2,758,356		1,817,228	
		3,396,512		2,579,417	
Liabilities:					
Creditors: amounts falling due within one year	12	811,047		642,950	
Net current assets			2,585,465		1,936,467
Total assets less current liabilities			2,598,754		1,952,941
Creditors: amounts falling due after one year	13		1,196,590		774,222
Total net assets	14		1,402,164		1,178,719
The funds of the charity:					
Restricted income funds	15		(34,990)		(68,295)
Unrestricted income funds:					
Designated funds		200,000		-	
General funds		1,237,154		1,247,014	
Total unrestricted funds			1,437,154		1,247,014
Total charity funds			1,402,164		1,178,719

Approved by the trustees on 6 October 2020 and signed on their behalf by Glyn Wilmshurst

Glyn Wilmshurst
Chair of Trustees

Sarcoma UK

Statement of cash flows

For the year ended 31 March 2020

	2020		2019	
	£	£	£	£
Cash flows from operating activities:				
Net income for the reporting period (as per the statement of financial activities)	223,445		11,727	
Depreciation charges	7,702		6,969	
Interest	(9,320)		(5,360)	
(Increase) / Decrease in debtors	126,959		(158,211)	
Increase / (Decrease) in creditors	590,465		310,378	
	<u> </u>		<u> </u>	
Net cash provided by operating activities		939,251		165,503
Cash flows from investing activities:				
Transferred (to) short term deposits	(2,926)		(2,685)	
Interest received	9,320		5,360	
Purchase of fixed assets	(4,517)		(3,177)	
	<u> </u>		<u> </u>	
Net cash (used in) investing activities		1,877		(502)
		<u> </u>		<u> </u>
Change in cash and cash equivalents in the year		941,128		165,001
Cash and cash equivalents at the beginning of the year		1,817,228		1,652,227
		<u> </u>		<u> </u>
Cash and cash equivalents at the end of the year		2,758,356		1,817,228
		<u> </u>		<u> </u>
Analysis of cash and cash equivalents				
		At 1 April		As at 31
		2019	Cash flows	March 2020
		£	£	£
Cash at bank and in hand		1,713,643	639,898	2,353,541
Notice deposits (less than three months)		103,585	301,230	404,815
		<u> </u>	<u> </u>	<u> </u>
Total cash and cash equivalents		1,817,228	941,128	2,758,356
		<u> </u>	<u> </u>	<u> </u>

1 Accounting policies

a) Statutory information

Sarcoma UK is a charitable company limited by guarantee and is incorporated in the United Kingdom. The registered office address (and principal place of business, if different from the registered office) is 49-51 East Road, London, N1 6AH.

b) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

c) Public benefit entity

The charitable company meets the definition of a public benefit entity under FRS 102.

d) Going concern

The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern. They have reviewed the cash flow forecast and budget in light of COVID-19 and still consider this to be the case.

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

e) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably.

Income from revenue grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met.

f) Donations of gifts, services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item or received the service, any conditions associated with the donation have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), volunteer time is not recognised so refer to the trustees' annual report for more information about their contribution.

On receipt, donated gifts, professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

g) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

1 Accounting policies (continued)

h) Fund accounting

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

i) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

Costs of raising funds relate to the costs incurred by the charitable company in inducing third parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising purpose

Expenditure on charitable activities includes the costs of raising sarcoma awareness, funding research and providing information and support, all undertaken to further the purposes of the charity and their associated support costs

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

j) Grants payable

Grants payable are made to third parties in furtherance of the charity's objects. Single or multi-year grants are accounted for when either the recipient has a reasonable expectation that they will receive a grant and the trustees have agreed to pay the grant without condition, or the recipient has a reasonable expectation that they will receive a grant and that any condition attaching to the grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

k) Allocation of support costs

Resources expended are allocated to the particular activity where the cost relates directly to that activity.

Support costs are those costs which do not in themselves constitute a charitable or fundraising activity, but are the central office functions necessary to support these activities. They include administration, finance, HR and office overhead costs.

Governance costs are the costs associated with the governance arrangements of the charity. These costs are associated with constitutional and statutory requirements and include any costs associated with the strategic management of the charity's activities.

Support and governance costs are re-allocated to each of the activities on the following basis which is an estimate, based on staff time, of the amount attributable to each activity:

Raising funds	32%
Research	20%
Information and support	29%
Awareness, campaigns and education	19%

l) Operating leases

Rentals payable under operating leases, where substantially all the risks and rewards of ownership remain with the lessor, are charged to the statement of financial activities on a straight line basis over the minimum lease term.

Notes to the financial statements

For the year ended 31 March 2020

1 Accounting policies (continued)

m) Tangible fixed assets

Items of equipment are capitalised where the purchase price exceeds £250. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures and fittings	5 years
Computer equipment	5 years

n) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

o) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

p) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

q) Pensions

The charitable company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charitable company in an independently administered fund. The pension cost charge represents contributions payable under the scheme by the charitable company to the fund. The charitable company has no liability under the scheme other than for the payment of those contributions.

2 Income from donations and legacies

	Unrestricted £	Restricted £	2020 Total £	Unrestricted £	Restricted £	2019 Total £
Donations and gifts	1,765,712	877,039	2,642,751	1,443,329	263,981	1,707,310
Legacies	35,000	10,000	45,000	150,865	-	150,865
Donated goods and services	12,000	-	12,000	-	-	-
	<u>1,812,712</u>	<u>887,039</u>	<u>2,699,751</u>	<u>1,594,194</u>	<u>263,981</u>	<u>1,858,175</u>

Donated goods and services include those donated to the Sarcoma UK Glitter Ball event from Diageo, Campari and Jelly Belly. Donated goods were also received for our London Marathon fundraising packs from Planet Organic.

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2020

3a Analysis of expenditure (current year)

	Charitable activities						2020 Total £	2019 Total £
	Cost of raising funds £	Research £	Information and support £	Awareness, campaigns and education £	Governance costs £	Support costs £		
Staff costs (Note 6)	252,525	85,855	174,377	133,132	24,647	185,087	855,623	668,828
Other staff costs	3,088	22,541	6,133	10,456	4,507	24,674	71,399	72,587
Research grants payable (Note 4)	-	905,596	-	-	-	-	905,596	655,646
Research support (development scheme)	-	11,006	-	-	-	-	11,006	-
Travel & subsistence	602	2,410	9,470	2,301	-	-	14,783	7,696
Fundraising fees	28,676	-	-	-	-	-	28,676	35,390
Fundraising materials	25,813	-	-	-	-	-	25,813	9,418
Events, participation & publicity costs	180,369	-	-	-	-	-	180,369	111,008
Fundraising appeals	17,491	-	-	-	-	-	17,491	341
Donor relationship management	6,798	-	-	-	-	-	6,798	14,137
PR & marketing	-	-	-	72,192	-	-	72,192	54,370
Support services	-	-	12,859	-	-	-	12,859	7,088
Awareness & campaigning projects	-	-	1,227	72,671	-	-	73,898	21,258
Information services	-	-	13,235	-	-	-	13,235	8,492
Office costs	-	-	-	-	-	133,389	133,389	124,797
Office communication costs	-	-	-	-	-	19,979	19,979	16,043
Membership subscriptions	3,786	1,606	102	438	1,495	381	7,808	4,767
Trustees development, expenses & meeting costs	-	-	-	-	4,148	-	4,148	5,546
Legal & professional	-	-	-	-	7,920	11,590	19,510	24,225
Insurance	-	-	-	-	-	2,728	2,728	2,656
Bank charges	-	-	-	-	-	624	624	546
Depreciation	-	-	-	-	-	7,702	7,702	6,969
	519,148	1,029,014	217,403	291,190	42,717	386,154	2,485,626	1,851,808
Support costs	123,712	76,516	112,986	72,940	-	(386,154)	-	-
Governance costs	13,685	8,464	12,499	8,069	(42,717)	-	-	-
Total expenditure 2020	656,545	1,113,994	342,888	372,199	-	-	2,485,626	1,851,808

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2020

3b Analysis of expenditure (prior year)

	Charitable activities						2019 Total £
	Cost of raising funds £	Research £	Information and support £	Awareness and education £	Governance costs £	Support costs £	
Staff costs (Note 6)	181,658	56,000	128,897	101,239	25,678	175,356	668,828
Other staff costs	22,776	11,632	10,289	6,417	2,495	18,978	72,587
Research grants payable (Note 4)	-	655,646	-	-	-	-	655,646
Travel & subsistence	91	2,592	3,859	456	601	97	7,696
Fundraising fees	35,390	-	-	-	-	-	35,390
Fundraising materials	9,418	-	-	-	-	-	9,418
Events, participation & publicity costs	111,008	-	-	-	-	-	111,008
Fundraising appeals	341	-	-	-	-	-	341
Donor relationship management	14,137	-	-	-	-	-	14,137
PR & marketing	-	-	-	54,370	-	-	54,370
Support services	-	-	7,088	-	-	-	7,088
Awareness & education projects	-	-	-	21,258	-	-	21,258
Information services	-	-	8,492	-	-	-	8,492
Office costs	-	-	-	-	-	124,797	124,797
Office communication costs	-	-	-	-	-	16,043	16,043
Membership subscriptions	1,996	1,435	-	-	1,336	-	4,767
Trustees development, expenses & meeting costs	-	-	-	-	5,546	-	5,546
Legal & professional	6,881	227	227	227	8,192	8,471	24,225
Insurance	-	-	-	-	-	2,656	2,656
Bank charges	-	-	-	-	-	546	546
Depreciation	-	-	-	-	-	6,969	6,969
	383,696	727,532	158,852	183,967	43,848	353,913	1,851,808
Support costs	107,866	69,705	115,098	61,244	-	(353,913)	-
Governance costs	13,364	8,636	14,260	7,588	(43,848)	-	-
Total expenditure 2019	504,926	805,873	288,210	252,799	-	-	1,851,808

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2020

4 Grant making

	2020	2019
	£	£
Grants to institutions:		
University College London		250,000
University College London Hospitals NHS Foundation Trust	80,389	23,464
University College London Cancer Institute		118,791
Institute of Cancer Research	120,000	144,490
Aston University	-	118,918
Imperial College London	119,873	-
University of Oxford	236,479	-
University of Birmingham	249,584	-
University of Leeds	116,374	-
	922,699	655,663
Queens University Belfast (underspend)	-	(17)
Newcastle Upon Tyne Hospital	(16,925)	-
University of Edinburgh (underspend)	(178)	-
	905,596	655,646
At the end of the year	905,596	655,646

Full details of grant making activities are disclosed on page 9-11 of the report of the trustees.

5 Net income / (expenditure) for the year

This is stated after charging / (crediting):

	2020	2019
	£	£
Depreciation	7,702	6,969
Interest received	(9,320)	(5,360)
Operating lease rentals:		
Property	90,389	88,284
Auditors' remuneration (excluding VAT):		
Audit	6,600	6,400

Notes to the financial statements

For the year ended 31 March 2020

6 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Staff costs were as follows:

	2020	2019
	£	£
Salaries and wages	740,593	581,300
Redundancy and termination payments	-	12,125
Social security costs	73,430	57,330
Employer's contribution to defined contribution pension schemes	30,500	17,668
Accrued holiday pay	11,100	405
	855,623	668,828

The following number of employees received employee benefits (excluding employer pension costs and national insurance contributions) during the year between:

	No.	No.
£90,000 - £99,999	1	-
£60,000 - £69,999	-	1

Full year costs included in 2018/19 published accounts, actual employee benefit was between £60,000 - £69,999 (see above).

The total employee benefits including pension contributions and national insurance of the key management personnel were £363,336 (2019: £319,750) incurred by 8 (2019: 7) employees.

The charity trustees were not paid or received any other benefits from employment with the charity in the year (2019: £nil). No charity trustee received payment for professional or other services supplied to the charity (2019: £nil).

Trustees' expenses represents the payment or reimbursement of travel and subsistence costs totalling £3,646 (2019: £3,573) incurred by 14 (2019: 14) members relating to attendance at meetings of the trustees. The costs shown in note 3 for trustees' development, expenses & meeting costs also include costs relating to trustee meeting lunches, which are not direct trustee expenses relating to attendance at meetings of the trustees.

7 Staff numbers

	2020	2019
	No.	No.
Raising funds	5	4
Research	2	3
Information and support	5	4
Awareness and campaigns	4	3
Support	6	7
	22	21

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2020

8 Related party transactions

Sarcoma UK Trustees and close family personally donated and raised £12,580. (2019: £20,111).

9 Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10 Tangible fixed assets

	Fixtures and fittings £	Computer equipment £	Total £
Cost or valuation			
At the start of the year	29,520	28,069	57,589
Additions in year	-	4,517	4,517
At the end of the year	29,520	32,586	62,106
Depreciation			
At the start of the year	18,480	22,635	41,115
Charge for the year	4,811	2,891	7,702
At the end of the year	23,291	25,526	48,817
Net book value			
At the end of the year	6,229	7,060	13,289
At the start of the year	11,040	5,434	16,474

All of the above assets are used for charitable purposes.

11 Debtors

	2020 £	2019 £
Other debtors	31,144	26,563
Prepayments	253,413	247,358
Accrued income	137,632	275,227
	422,189	549,148

12 Creditors: amounts falling due within one year

	2020 £	2019 £
Trade creditors	11,346	31,584
Taxation and social security	21,481	14,664
Other creditors	5,164	3,632
Accruals	108,543	26,673
Deferred income	1,000	-
Grants payable	663,513	566,397
	811,047	642,950

13 Creditors: amounts falling due after one year

	2020 £	2019 £
Grants payable:		
1 - 2 years	705,836	372,991
2 - 5 years	490,754	401,231
	1,196,590	774,222

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2020

14a Analysis of net assets between funds (current year)

	General unrestricted £	Designated £	Restricted £	Total funds £
Tangible fixed assets	13,289	-	-	13,289
Net current assets	2,420,455	200,000	(34,990)	2,585,465
Long term liabilities	(1,196,590)	-	-	(1,196,590)
Net assets at 31 March 2020	1,237,154	200,000	(34,990)	1,402,164

14b Analysis of net assets between funds (prior year)

	General unrestricted £	Designated £	Restricted £	Total funds £
Tangible fixed assets	14,779	-	1,695	16,474
Net current assets	2,006,457	-	(69,990)	1,936,467
Long term liabilities	(774,222)	-	-	(774,222)
Net assets at 31 March 2019	1,247,014	-	(68,295)	1,178,719

15a Movements in funds (current year)

	At 1 April 2019 £	Income and gains £	Expenditure and losses £	Transfers £	At 31 March 2020 £
Restricted funds:					
Sarcoma Trust	10	-	-	-	10
Infrastructure development	1,695	-	(1,695)	-	-
Research	(70,000)	830,546	(784,046)	(11,500)	(35,000)
Information and support	-	29,806	(41,306)	11,500	-
Awareness, campaigns and education	-	26,687	(26,687)	-	-
Total restricted funds	(68,295)	887,039	(853,734)	-	(34,990)
Unrestricted funds:					
<i>Designated funds:</i>					
Research	-	-	-	100,000	100,000
Information and support	-	-	-	100,000	100,000
Total designated funds	-	-	-	200,000	200,000
General funds	1,247,014	1,822,032	(1,631,892)	(200,000)	1,237,154
Total unrestricted funds	1,247,014	1,822,032	(1,631,892)	-	1,437,154
Total funds	1,178,719	2,709,071	(2,485,626)	-	1,402,164

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2020

15b Movements in funds (prior year)

	At 31 March 2018 £	Income and gains £	Expenditure and losses £	Transfers £	At 1 April 2019 £
Restricted funds:					
Sarcoma Trust	10	-	-	-	10
Infrastructure development	3,392	-	(1,697)	-	1,695
Research	-	263,981	(333,981)	-	(70,000)
Total restricted funds	3,402	263,981	(335,678)	-	(68,295)
Unrestricted funds:					
Research designated funds	500,000	-	(400,165)	(99,835)	-
General funds	663,590	1,599,554	(1,115,965)	99,835	1,247,014
Total unrestricted funds	1,163,590	1,599,554	(1,516,130)	-	1,247,014
Total funds	1,166,992	1,863,535	(1,851,808)	-	1,178,719

Purposes of restricted funds:

Sarcoma Trust

These funds represent the amounts retained within the Sarcoma Trust after becoming a linked charity with Sarcoma UK.

Infrastructure Development

Expenditure against the fund relates to depreciation charges for the year, on assets purchased to develop the infrastructure of Sarcoma UK.

Research

These funds are to be used specifically towards research grants, as requested by the donor. In 2018/19 Sarcoma UK issued a grant for a Phd for which we subsequently received funding from the McAlpine Trust. The Trust is funding Sarcoma UK £35,000 each year for three years, the first payment was received in 2018/19, the second payment in 2019/20 and third payment will be received in 2020/21. Consequently the restricted fund to which this funding relates was in deficit at 31st March 2020.

Information and Support

These funds are to be used specifically towards the provision of support and information for the sarcoma community, as requested by the donor.

Awareness, Campaigns and Education

These funds are to be used specifically towards raising awareness and improving standards of treatment and care, as requested by the donor.

Purposes of designated funds:

Research

These funds represent those designated by the trustees towards our core research costs in 2020/21. These core costs include research grants awarded and research management costs.

Information and Support

These funds represent those designated by the trustees towards our information and support service in 2020/21. These costs include the running of our support line service and production of patient information.

Notes to the financial statements

For the year ended 31 March 2020

16 Operating lease commitments

The charity's total future minimum lease payments under non-cancellable operating leases is as follows for each of the following periods

	Property		Equipment	
	2020	2019	2020	2019
	£	£	£	£
Less than one year	23,051	22,597	828	473
	23,051	22,597	828	473

17 Legal status of the charity

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.